KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) Times Interest Earned (2016 - 2025)

Historic Times Interest Earned for Halozyme Therapeutics (HALO) over the last 13 years, with Q3 2025 value amounting to $50.73.

  • Halozyme Therapeutics' Times Interest Earned rose 4061.94% to $50.73 in Q3 2025 from the same period last year, while for Sep 2025 it was $41.53, marking a year-over-year increase of 6346.87%. This contributed to the annual value of $30.48 for FY2024, which is 6938.59% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Times Interest Earned stood at $50.73 for Q3 2025, which was up 4061.94% from $46.07 recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Times Interest Earned high stood at $53.11 for Q2 2021, and its period low was $10.97 during Q2 2022.
  • Its 5-year average for Times Interest Earned is $29.09, with a median of $25.91 in 2024.
  • As far as peak fluctuations go, Halozyme Therapeutics' Times Interest Earned soared by 438426.38% in 2021, and later tumbled by 7933.88% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Times Interest Earned (Quarter) stood at $27.51 in 2021, then crashed by 40.74% to $16.3 in 2022, then rose by 18.72% to $19.36 in 2023, then skyrocketed by 99.72% to $38.66 in 2024, then surged by 31.22% to $50.73 in 2025.
  • Its Times Interest Earned stands at $50.73 for Q3 2025, versus $46.07 for Q2 2025 and $31.28 for Q1 2025.